<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04939350</url>
  </required_header>
  <id_info>
    <org_study_id>IDRCB 2021-A00343-38</org_study_id>
    <nct_id>NCT04939350</nct_id>
  </id_info>
  <brief_title>Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021</brief_title>
  <acronym>VACCIR</acronym>
  <official_title>Evaluation of the Vaccination Coverage in a Prospective Cohort of Cirrhotic Patients Followed in the General Hospitals in France in 2021</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Sud Francilien</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Sud Francilien</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the purpose of this study is to estimate vacinal coverage against hepatitis A and B viruses,&#xD;
      pneumococcus, diphtheria/tetanos and poliomyelitis, influenza virus and covid in cirrhotic&#xD;
      patients followed in general hospitals of France and to show the&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cirrhosis is a serious liver disease very common in France, affecting nearly 200,000 people.&#xD;
      These patients have an impaired immune response. They are, therefore, more frequently prone&#xD;
      to bacterial, viral and fungal infections and these are more severe with high mortality.&#xD;
      30-50% of cirrhotics admitted to a hospital ward have sepsis, with pneumococcal bacterial&#xD;
      infections being particularly severe. The risk of developing seasonal influenza is 5.7 times&#xD;
      higher in cirrhotics with a risk of mortality multiplied by 169. COVID19 infection is&#xD;
      responsible for a very high mortality (34%) in case of severe resuscitation form. Acute&#xD;
      infections with hepatitis A (HAV) and B (HBV) viruses frequently lead to worsening liver&#xD;
      failure decompensating to cirrhosis, and sometimes life-threatening fulminant hepatitis.&#xD;
      Finally, chronic infection with the hepatitis B virus combined with another etiology of&#xD;
      cirrhosis accelerates the course of liver disease and promotes the occurrence of&#xD;
      hepatocellular carcinoma.&#xD;
&#xD;
      Limiting the incidence of viral and bacterial infections in these patients is crucial. The&#xD;
      High Authority of Health (HAS) published recommendations in 2007 advising patients with&#xD;
      cirrhosis vaccinations against hepatitis A and B viruses, influenza and against bacterial&#xD;
      pneumococcal infections, confirmed by the High Council of Public Health.&#xD;
&#xD;
      There are few data on vaccination coverage among cirrhotic patients. An unpublished French&#xD;
      study from 2000 revealed low vaccination rates: 34% for pneumococcus, 55% for influenza, 32&#xD;
      to 42% for the hepatitis B virus and 20 to 38% for the hepatitis A virus. No recent studies&#xD;
      have assessed the impact of the HAS recommendations.&#xD;
&#xD;
      The purpose of this study is to estimate vacinal coverage against hepatitis A and B viruses,&#xD;
      pneumococcus, diphtheria/tetanos and poliomyelitis, influenza virus and covid in cirrhotic&#xD;
      patients followed in general hospitals of France&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>percentage fully immunization coverage</measure>
    <time_frame>Day 0</time_frame>
    <description>percentage of patients fully vaccinated against polio DT, seasonal influenza, HAV, HBV, pneumococcal and COVID19 in our sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage DTpolio immunization coverage</measure>
    <time_frame>Day 0</time_frame>
    <description>Percentage of vaccination against DTPolio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage HAV immunization coverage</measure>
    <time_frame>Day 0</time_frame>
    <description>Percentage of vaccination against HAV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage HBV immunization coverage</measure>
    <time_frame>Day 0</time_frame>
    <description>Percentages of vaccination against HBV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage Pneumococcal immunization coverage</measure>
    <time_frame>Day 0</time_frame>
    <description>Percentages of vaccination against pneumococcaL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage Influenza virus immunization coverage</measure>
    <time_frame>Day 0</time_frame>
    <description>Percentage of vaccination against seasonal influenza</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage COVID immunization coverage</measure>
    <time_frame>Day 0</time_frame>
    <description>Percentage of vaccination against COVID19</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Cirrhosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire</intervention_name>
    <description>patients will complete a vaccination questionnaire</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All cirrhotic patients followed for at least 6 months in consultation or hospitalization&#xD;
        during the duration of the study in the general hospitals members of the ANGH participating&#xD;
        in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult patient&#xD;
&#xD;
          -  histologically proven or asserted cirrhosis on a combination of clinical, biological,&#xD;
             endoscopic and radiological criteria&#xD;
&#xD;
          -  follow-up of cirrhosis &gt; 6 months&#xD;
&#xD;
          -  subject informed of the study and not having objected to it.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  immunosuppression not related to liver disease: HIV, variable common immune&#xD;
             deficiency, chemotherapy, anatomical splenectomy, immunosuppressive treatments for&#xD;
             non-hepatic disease&#xD;
&#xD;
          -  vaccine contraindication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Aurore BARON, MD</last_name>
    <phone>(33) 1 61 69 30 75</phone>
    <email>aurore.baron@chsf.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline TOURTE</last_name>
    <phone>(33) 1 61 69 31 50</phone>
    <email>caroline.tourte@chsf.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Sud Francilien</name>
      <address>
        <city>Corbeil-essonnes Cedex</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurore BARON</last_name>
      <phone>(33) 1 61 69 30 75</phone>
      <email>aurore.baron@chsf.fr</email>
    </contact>
    <investigator>
      <last_name>Aurore BARON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccinal coverage</keyword>
  <keyword>vaccination</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>cirrhotic</keyword>
  <keyword>COVID</keyword>
  <keyword>hepatitis B</keyword>
  <keyword>hepatitis A</keyword>
  <keyword>influenzae virus</keyword>
  <keyword>pneumococcus</keyword>
  <keyword>tetanus</keyword>
  <keyword>poliomyelitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

